MedTrace Logo

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

NCT01175824 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 478

Last updated 2014-02-24

Study results available
· View outcomes & findings →

Summary

The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Lispro Low Mixture (LM)

Participant-dependent dose, administered subcutaneously for 24 weeks

DRUG

Insulin Glargine

Participant-dependent dose, administered subcutaneously for 24 weeks

DRUG

Prandial Insulin Lispro

Participant-dependent dose, administered subcutaneously for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Argentina
  • Brazil
  • China
  • Egypt
  • India
  • South Korea
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01175824 on ClinicalTrials.gov